Vimian Group AB (publ) (VIMGF)
OTCMKTS · Delayed Price · Currency is USD
4.300
0.00 (0.00%)
At close: Jul 14, 2025

Vimian Group AB Company Description

Vimian Group AB (publ) engages in the animal health business worldwide.

It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.

It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name.

Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

Vimian Group AB (publ)
CountrySweden
Founded2020
IndustryDiagnostics & Research
SectorHealthcare
Employees1,200
CEOCarl-Johan Boudrie

Contact Details

Address:
Riddargatan 19
Stockholm, 11457
Sweden
Websitevimian.com

Stock Details

Ticker SymbolVIMGF
ExchangeOTCMKTS
Fiscal YearJanuary - December
Reporting CurrencyEUR
ISIN NumberSE0015961982
SIC Code3841

Key Executives

NamePosition
Alireza TajbakhshHead and Chief Executive Officer of VetFamily
Guy C. SporriChief Executive Officer of Movora
Stefano SantarelliChief Executive Officer of Indical Bioscience
Magnus KjellbergChief Executive Officer of Nextmune
Carl-Johan Zetterberg BoudrieChief Financial Officer and Interim Chief Executive Officer
Maria Dahllof TullbergHead of IR, Communications and Sustainability
Carl-Johan EhnGeneral Counsel
Bart BremerChief People Officer
Martin BengtsonHead of M&A